用硝化甘油治疗前列腺癌显示出治愈前列腺癌的潜力

　

Using Nitroglycerin To Treat Prostate Cancer Shows Potential To Halt Disease

由NutritonReview.org - 20102378年2月12日
加拿大皇后大学的研究人员发现，使用极低剂量的硝酸甘油治疗前列腺癌可能会减缓甚至阻止疾病的发展，而没有目前治疗的严重副作用。这是首次使用硝化甘油治疗前列腺癌的临床试验的结果。这项为期24个月的二期研究针对29名前列腺手术或放疗后前列腺特异性抗原(PSA)水平升高的男性。PSA水平是癌症进展的重要预测因子。

　

 
“我们非常兴奋地看到显著减缓疾病的进展的证据就是PSA水平,并在许多人看到这个结果。” 罗伯特•西门子说，西门子是这项研究的领导人,皇后大学的泌尿学教授,金斯敦总医院 的泌尿科医生。
 
研究人员对这一结果感到鼓舞，尤其是因为对于PSA水平在手术或放疗后升高的男性来说，安全有效的治疗是有限的。他们指出，还需要进行进一步的试验，以确认这个非常小的研究的结果。

　

 
这些人接受了低剂量、缓释硝酸甘油贴片治疗，并监测他们的PSA水平。在完成这项研究的17名患者中，除了一名患者外，所有人的癌症进展速度都有稳定或下降的迹象，这是通过他们的PSA倍增时间来衡量的。
 
一个多世纪以来，硝化甘油被大量用于治疗心绞痛。这项试验是基于皇后医院进行的临床前研究的一个关键发现，该发现表明一氧化氮的减少在肿瘤进展中起着重要作用，这种进展可以通过低剂量的硝酸甘油来阻止。
 
在美国，每年约有23.5万名男性被诊断出患有前列腺癌，而在加拿大则是20,700人。在接受根治性前列腺切除术和/或放疗的患者中，估计有30%到50%的患者会出现癌症复发。
 
这项研究由皇后大学的研究人员罗伯特·西门子、杰里米·希顿、迈克尔·亚当斯、琼·卡瓦卡米和查尔斯·格雷厄姆共同完成，研究结果刊登在最近一期的《泌尿学》杂志上。
 
利用硝酸甘油和类似化合物治疗癌症的研究。亚当斯、格雷厄姆和希顿已经在全球范围内获得了10项专利。皇后大学的技术转让办公室PARTEQ创新公司已经将部分知识产权授权给了Nometics Inc.，这是一家名为Nometics Inc.的公司，该公司正在研发基于此和相关研究的产品和治疗方法。
 
“这项经过同行评审的研究是我们第一次明确的临床证据，证明低剂量的一氧化氮疗法为前列腺癌患者提供了一种新的非侵入性治疗方案，”Nometics的首席执行官罗伯特·本德(Robert Bender)说。“我们打算在2010年开展更广泛的临床试验，以证实和扩大这些结果。”

　

　

　

Using Nitroglycerin To Treat Prostate Cancer Shows Potential To Halt Disease

By NutritonReview.org - February 12, 20102378

Treatment of prostate cancer using a very low dose of nitroglycerin may slow and even halt the progression of the disease without the severe side effects of current treatments, Queen’s University researchers have discovered. The findings are the result of the first-ever clinical trial using nitroglycerin to treat prostate cancer. The 24-month, Phase II study targeted 29 men with increasing levels of prostate-specific antigen (PSA) following prostate surgery or radiation. PSA levels are a key predictor of cancer progression.

 

“We were very excited to see a significant slowing in the progression of the disease as evidenced by the men’s PSA levels, and to see this result in many of the men who completed the study,” says Robert Siemens, the leader of the study and a Professor of Urology at Queen’s University and urologist at Kingston General Hospital.

 

The researchers are encouraged by the results, particularly because safe and effective treatments for men with rising PSA levels following surgery or radiation are limited. They note that further testing needs to be done to confirm the results of this very small study.

 

The men were treated with a low-dose, slow-release nitroglycerin skin patch and their PSA levels monitored. Of the 17 patients who completed the study, all but one showed a stabilization or decrease in the rate of cancer progression, as measured by their PSA Doubling Time.

 

Nitroglycerin has been used at significantly higher doses for more than a century to treat angina. This trial was based on a key finding from pre-clinical research carried out at Queen’s, which showed that decreases in nitric oxide play an important role in tumor progression and that this progression can be stopped by low-dose nitroglycerin.

 

Prostate cancer is diagnosed in approximately 235,000 men per year in the United States and 20,700 in Canada. Of patients who have undergone radical prostatectomy and/or radiation treatment, it is estimated that 30 to 50 percent will experience a recurrence of cancer.

 

Results of the study, conducted by Queen’s University researchers Robert Siemens, Jeremy Heaton, Michael Adams, Jun Kawakami and Charles Graham, appeared in a recent issue of the journal Urology.

 

Research into the use of nitroglycerin and similar compounds for the treatment of cancer by Drs. Adams, Graham and Heaton has resulted in the issue of 10 patents worldwide. PARTEQ Innovations, the technology transfer office of Queen’s, has licensed some of this intellectual property to Nometics Inc., a Queen’s spinoff company, which is developing products and therapies based on this and related research.

 

“This peer-reviewed research is our first clear clinical evidence that low-dose nitric oxide therapy offers prostate cancer patients a new non-invasive treatment option,” says Robert Bender, CEO of Nometics. “It is our intention to start broader clinical trials in 2010 to confirm and expand these results.”

 

Story Source:

Adapted from materials provided by Queen’s University, via EurekAlert!, a service of AAAS.

Using Nitroglycerin To Treat Prostate Cancer Shows Potential To Halt Disease | Nutrition Review  https://nutritionreview.org/2010/02/using-nitroglycerin-to-treat-prostate-cancer-shows-potential-to-halt-disease/